自90年代以来,肝癌已上升为我国恶性肿瘤的第二位,中国每年大约有13万患者死于肝癌,占全球肝癌死亡总数的42%。原发性肝癌预后差,自然生存期不超过3～6个月,目前对肝癌最有效的治疗方法是手术治疗,但由于肿瘤发展快速,绝大多数患者确诊时已属晚期,且肝肿瘤的肝外转移在确诊时约为25%,尸检报告达90%。文献报道直径小于3厘米的小肝癌合并肝硬化的发生率达80%,使得能接受手术治疗者仅占肝癌总数的10%～40%,即使 Since the 1990s, liver cancer has risen to the second place in China. About 130,000 people die of liver cancer each year in China, accounting for 42% of the global liver cancer deaths. Primary liver cancer prognosis is poor, the natural survival of no more than 3 to 6 months, the current treatment of liver cancer is the most effective treatment for surgery, but because of rapid tumor development, the vast majority of patients diagnosed late, and liver tumors Extrahepatic metastases at diagnosis of about 25%, autopsy reported 90%. The incidence of cirrhosis of small hepatocellular carcinoma with a diameter of less than 3 cm has been reported in the literature to be 80%, making it only 10% to 40% of the total number of liver cancers that can be treated surgically